Skip to main content
Clinical Trials/NL-OMON36863
NL-OMON36863
Not Yet Recruiting
Phase 2

Maternal pharmacokinetics and pharmacodynamics of nicardipine (iv) during treatment of severe hypertension in pregnancy. - Nicardipine PkPd study

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
preeclampsia
Sponsor
Erasmus MC, Universitair Medisch Centrum Rotterdam
Enrollment
40
Status
Not Yet Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Observational non invasive

Investigators

Eligibility Criteria

Inclusion Criteria

  • Pregnant patients with preeclampsia (hypertension and protein/creatinine ratio \>\= 30mg/mmol or \>\= 300mg protein/24hours) complicated with severe hypertension (systolic bloodpressure \>\= 160mmHg and/or diastolic blood pressure \>\= 110mmHg);gestational age \>\= 20 weeks;working knowledge of Dutch language

Exclusion Criteria

  • Fetal indication for immediate delivery, ie. signs of fetal distress: spontaneous repeated persistent unprovoked decelerations on CTG;Fetal death or major fetal congenital anomalies or estimated fetal weight below 500 grams;Placental abruption;Concomitant medication: nifedipine, cimetidine, labetalol;Clinically relevant pulmonary edema, defined as clinically relevant respiratory failure or severe respiratory distress requiring oxygen supplementation (more than 10 litres), with rales and/or pulse oximetry of \<94% on room air;Eclampsia;Suspicion of (sub)capsular liverhematoma on physical examination;Renal failure (creatinine clearance \< 40 mL/min)
  • Suspicion of cerebro\-vascular incident on physical examination
  • Suspicion of trombo\-embolism on physical examination
  • Other severe maternal complications
  • Maternal age \<16 years
  • Mentally incapacitated patient
  • Impossible to place an intra\-arterial catheter.

Outcomes

Primary Outcomes

Not specified

Similar Trials